Vaccines based on structure-based design provide protection against infectious diseases

Sunil Thomas, Bruce A. Luxon

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Vaccines elicit immune responses, provide protection against microorganisms and are considered as one of the most successful medical interventions against infectious diseases. Vaccines can be produced using attenuated virus or bacteria, recombinant proteins, bacterial polysaccharides, carbohydrates or plasmid DNA. Conventional vaccines rely on the induction of immune responses against antigenic proteins to be effective. The genetic diversity of microorganisms, coupled with the high degree of sequence variability in antigenic proteins, presents a challenge to developing broadly effective conventional vaccines. The observation that whole protein antigens are not necessarily essential for inducing immunity has led to the emergence of a new branch of vaccine design termed 'structural vaccinology'. Structure-based vaccines are designed on the rationale that protective epitopes should be sufficient to induce immune responses and provide protection against pathogens. Recent studies demonstrated that designing structure-based vaccine candidates with multiple epitopes induce a higher immune response. As yet there are no commercial vaccines available based on structure-based design and most of the structure-based vaccine candidates are in the preclinical stages of development. This review focuses on recent advances in structure-based vaccine candidates and their application in providing protection against infectious diseases.

    Original languageEnglish (US)
    Pages (from-to)1301-1311
    Number of pages11
    JournalExpert Review of Vaccines
    Volume12
    Issue number11
    DOIs
    StatePublished - 2013

    Fingerprint

    Communicable Diseases
    Vaccines
    Epitopes
    Bacterial Polysaccharides
    Antigenic Variation
    Proteins
    Recombinant Proteins
    Immunity
    Plasmids
    Carbohydrates
    Viruses
    Bacteria
    Antigens
    DNA

    Keywords

    • epitope
    • infectious disease
    • structure-based design
    • vaccine

    ASJC Scopus subject areas

    • Immunology
    • Drug Discovery
    • Pharmacology
    • Molecular Medicine

    Cite this

    Vaccines based on structure-based design provide protection against infectious diseases. / Thomas, Sunil; Luxon, Bruce A.

    In: Expert Review of Vaccines, Vol. 12, No. 11, 2013, p. 1301-1311.

    Research output: Contribution to journalArticle

    Thomas, Sunil ; Luxon, Bruce A. / Vaccines based on structure-based design provide protection against infectious diseases. In: Expert Review of Vaccines. 2013 ; Vol. 12, No. 11. pp. 1301-1311.
    @article{eafec1af6b144d308c0c5db4fa717f2a,
    title = "Vaccines based on structure-based design provide protection against infectious diseases",
    abstract = "Vaccines elicit immune responses, provide protection against microorganisms and are considered as one of the most successful medical interventions against infectious diseases. Vaccines can be produced using attenuated virus or bacteria, recombinant proteins, bacterial polysaccharides, carbohydrates or plasmid DNA. Conventional vaccines rely on the induction of immune responses against antigenic proteins to be effective. The genetic diversity of microorganisms, coupled with the high degree of sequence variability in antigenic proteins, presents a challenge to developing broadly effective conventional vaccines. The observation that whole protein antigens are not necessarily essential for inducing immunity has led to the emergence of a new branch of vaccine design termed 'structural vaccinology'. Structure-based vaccines are designed on the rationale that protective epitopes should be sufficient to induce immune responses and provide protection against pathogens. Recent studies demonstrated that designing structure-based vaccine candidates with multiple epitopes induce a higher immune response. As yet there are no commercial vaccines available based on structure-based design and most of the structure-based vaccine candidates are in the preclinical stages of development. This review focuses on recent advances in structure-based vaccine candidates and their application in providing protection against infectious diseases.",
    keywords = "epitope, infectious disease, structure-based design, vaccine",
    author = "Sunil Thomas and Luxon, {Bruce A.}",
    year = "2013",
    doi = "10.1586/14760584.2013.840092",
    language = "English (US)",
    volume = "12",
    pages = "1301--1311",
    journal = "Expert Review of Vaccines",
    issn = "1476-0584",
    publisher = "Expert Reviews Ltd.",
    number = "11",

    }

    TY - JOUR

    T1 - Vaccines based on structure-based design provide protection against infectious diseases

    AU - Thomas, Sunil

    AU - Luxon, Bruce A.

    PY - 2013

    Y1 - 2013

    N2 - Vaccines elicit immune responses, provide protection against microorganisms and are considered as one of the most successful medical interventions against infectious diseases. Vaccines can be produced using attenuated virus or bacteria, recombinant proteins, bacterial polysaccharides, carbohydrates or plasmid DNA. Conventional vaccines rely on the induction of immune responses against antigenic proteins to be effective. The genetic diversity of microorganisms, coupled with the high degree of sequence variability in antigenic proteins, presents a challenge to developing broadly effective conventional vaccines. The observation that whole protein antigens are not necessarily essential for inducing immunity has led to the emergence of a new branch of vaccine design termed 'structural vaccinology'. Structure-based vaccines are designed on the rationale that protective epitopes should be sufficient to induce immune responses and provide protection against pathogens. Recent studies demonstrated that designing structure-based vaccine candidates with multiple epitopes induce a higher immune response. As yet there are no commercial vaccines available based on structure-based design and most of the structure-based vaccine candidates are in the preclinical stages of development. This review focuses on recent advances in structure-based vaccine candidates and their application in providing protection against infectious diseases.

    AB - Vaccines elicit immune responses, provide protection against microorganisms and are considered as one of the most successful medical interventions against infectious diseases. Vaccines can be produced using attenuated virus or bacteria, recombinant proteins, bacterial polysaccharides, carbohydrates or plasmid DNA. Conventional vaccines rely on the induction of immune responses against antigenic proteins to be effective. The genetic diversity of microorganisms, coupled with the high degree of sequence variability in antigenic proteins, presents a challenge to developing broadly effective conventional vaccines. The observation that whole protein antigens are not necessarily essential for inducing immunity has led to the emergence of a new branch of vaccine design termed 'structural vaccinology'. Structure-based vaccines are designed on the rationale that protective epitopes should be sufficient to induce immune responses and provide protection against pathogens. Recent studies demonstrated that designing structure-based vaccine candidates with multiple epitopes induce a higher immune response. As yet there are no commercial vaccines available based on structure-based design and most of the structure-based vaccine candidates are in the preclinical stages of development. This review focuses on recent advances in structure-based vaccine candidates and their application in providing protection against infectious diseases.

    KW - epitope

    KW - infectious disease

    KW - structure-based design

    KW - vaccine

    UR - http://www.scopus.com/inward/record.url?scp=84887346464&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84887346464&partnerID=8YFLogxK

    U2 - 10.1586/14760584.2013.840092

    DO - 10.1586/14760584.2013.840092

    M3 - Article

    C2 - 24090172

    AN - SCOPUS:84887346464

    VL - 12

    SP - 1301

    EP - 1311

    JO - Expert Review of Vaccines

    JF - Expert Review of Vaccines

    SN - 1476-0584

    IS - 11

    ER -